CRADD Antibody

Code CSB-PA005938HA01HU
Size US$166
Order now
Image
  • Immunofluorescence staining of A549 cells with CSB-PA005938HA01HU at 1:530, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) CRADD Polyclonal antibody
Uniprot No.
Target Names
CRADD
Alternative Names
CASP2 and RIPK1 domain containing adaptor with death domain antibody; Caspase and RIP adapter with death domain antibody; Caspase and RIP adaptor with death domain antibody; Cradd antibody; CRADD_HUMAN antibody; Death adaptor molecule RAIDD antibody; Death domain containing protein CRADD antibody; Death domain-containing protein CRADD antibody; MGC9163 antibody; RIP associated ICH1/CED3 homologous protein with death domain antibody; RIP associated protein with a death domain antibody; RIP-associated protein with a death domain antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Death domain-containing protein CRADD protein (1-199AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The CRADD Antibody (Product code: CSB-PA005938HA01HU) is Non-conjugated. For CRADD Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA005938HB01HU CRADD Antibody, HRP conjugated ELISA
FITC CSB-PA005938HC01HU CRADD Antibody, FITC conjugated
Biotin CSB-PA005938HD01HU CRADD Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IF
Recommended Dilution
Application Recommended Dilution
IF 1:500-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Adapter protein that associates with PIDD1 and the caspase CASP2 to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis. Also recruits CASP2 to the TNFR-1 signaling complex through its interaction with RIPK1 and TRADD and may play a role in the tumor necrosis factor-mediated signaling pathway.
Gene References into Functions
  1. Whole exome sequencing (WES) of an affected fetus, and subsequent Sanger sequencing of the second fetus, revealed a homozygous frameshift variant in CRADD, which encodes an adaptor protein that interacts with PIDD and caspase-2 to initiate apoptosis PMID: 28686357
  2. The megalencephaly, lissencephaly variant, and intellectual disability associated with loss of CRADD/caspase-2-mediated apoptosis imply a role for CRADD/caspase-2 signaling in development of the human cerebral cortex. PMID: 27773430
  3. The adaptor molecule RAIDD coordinates IKKepsilon and IRF7 interaction to ensure efficient expression of type I interferon. PMID: 27606466
  4. define a novel function for CRADD in endothelial cells as an inducible suppressor of BCL10, a key mediator of responses to proinflammatory agonists PMID: 24958727
  5. Crystals are trigonal and belong to space group P3(1)21 (or its enantiomorph P3(2)21) with unit-cell parameters a = 56.3, b = 56.3, c = 64.9 A and gamma = 120 degrees . PMID: 19582216
  6. Study identified sequence variants in the known disease-causing genes SLC6A3 and FLVCR1, and present evidence to strongly support the pathogenicity of variants identified in TUBGCP6, BRAT1, SNIP1, CRADD, and HARS. PMID: 22279524
  7. point mutations on RAIDD (R147E) and on PIDD (Y814A) exert a dominant negative effect on the formation of the PIDDosome, and that this effect cannot be applied after the PIDDosome has been formed PMID: 20406701
  8. The expressions of PIDD and RAIDD are upregulated during tumour progression in renal cell carcinomas. PMID: 20208132
  9. As a first step towards elucidating the molecular mechanisms of caspase-2 activation, data report the crystal structure of the RAIDD death domain at 2.0 A resolution. PMID: 16434054
  10. PIDD death domain (DD) and RAIDD DD assemble into an oligomeric complex. Within the PIDDosome, the interaction between PIDD and RAIDD is mediated by a homotypic interaction between their death domains. PMID: 17329820
  11. impaired expression of RAIDD in drug induced apoptosis may play a role in the multidrug resistance of osteosarcoma cells PMID: 19125251

Show More

Hide All

Involvement in disease
Mental retardation, autosomal recessive 34, with variant lissencephaly (MRT34)
Subcellular Location
Cytoplasm. Nucleus.
Tissue Specificity
Constitutively expressed in most tissues, with particularly high expression in adult heart, testis, liver, skeletal muscle, fetal liver and kidney.
Database Links

HGNC: 2340

OMIM: 603454

KEGG: hsa:8738

STRING: 9606.ENSP00000327647

UniGene: Hs.38533

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*